05.24.19
Catalent is launching its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologics. OneBio aims to address the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework.
OneBio Suite aims to reduce timelines, risk and complexity by providing customers with a single contract, program manager, and development timeline from cell line to clinical supply with harmonized quality systems. Catalent’s experience progressing biologic drugs to market includes more than 115 global clinical trials and 11 commercially marketed monoclonal antibodies using the company’s GPEx cell line development technology, and 20 approved products through fill/finish and commercial supply to global markets.
“Time is often lost for sponsors on the path to clinic from contract negotiation, site inspections, handoffs, and poor communication between multiple vendors,” commented Bernie Clark, vice president, Marketing & Strategy, Catalent Biologics & Specialty Drug Delivery. “Through our new OneBio Suite, Catalent is uniquely positioned to provide an integrated offering that can accelerate biologic development potentially shaving weeks to months off standard timelines and allowing our customers to get to clinic and market faster.”
Catalent (Booth 3101) will be exhibiting at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.
Additionally, Catalent’s Steven Hager, Ph.D., senior director, Technical Support, will present Cell Line Development Strategies for Difficult to Express Proteins as part of the Emerging Techniques, Technologies and Strategies track. His presentation takes place on Wednesday, June 5 from 11:40 a.m.-12:00 p.m. at the BPI Theater, Booth #3211 in the BioProcess Zone.
From 1:45 – 2:30 p.m., Dr. Hager will also participate in a Single Use Systems Versus Stainless Steel roundtable, also at the BPI Theater.
OneBio Suite aims to reduce timelines, risk and complexity by providing customers with a single contract, program manager, and development timeline from cell line to clinical supply with harmonized quality systems. Catalent’s experience progressing biologic drugs to market includes more than 115 global clinical trials and 11 commercially marketed monoclonal antibodies using the company’s GPEx cell line development technology, and 20 approved products through fill/finish and commercial supply to global markets.
“Time is often lost for sponsors on the path to clinic from contract negotiation, site inspections, handoffs, and poor communication between multiple vendors,” commented Bernie Clark, vice president, Marketing & Strategy, Catalent Biologics & Specialty Drug Delivery. “Through our new OneBio Suite, Catalent is uniquely positioned to provide an integrated offering that can accelerate biologic development potentially shaving weeks to months off standard timelines and allowing our customers to get to clinic and market faster.”
Catalent (Booth 3101) will be exhibiting at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.
Additionally, Catalent’s Steven Hager, Ph.D., senior director, Technical Support, will present Cell Line Development Strategies for Difficult to Express Proteins as part of the Emerging Techniques, Technologies and Strategies track. His presentation takes place on Wednesday, June 5 from 11:40 a.m.-12:00 p.m. at the BPI Theater, Booth #3211 in the BioProcess Zone.
From 1:45 – 2:30 p.m., Dr. Hager will also participate in a Single Use Systems Versus Stainless Steel roundtable, also at the BPI Theater.
